# Sympathetic Mechanisms in Obesity-Crossover Design

> **NCT05312892** · PHASE1,PHASE2 · RECRUITING · sponsor: **Vanderbilt University Medical Center** · enrollment: 12 (estimated)

## Conditions studied

- Obesity
- Hypertension

## Interventions

- **DRUG:** Amlodipine
- **DRUG:** Moxonidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05312892
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-20
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05312892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05312892, "Sympathetic Mechanisms in Obesity-Crossover Design". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05312892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*